A phase I study of Nanobodies targeting a G-protein-coupled receptor (GPCR) in the treatment of inflammation
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Single-domain antibodies (Primary)
- Indications Inflammation
- Focus Adverse reactions
- 12 May 2016 According to an Ablynx media release, Novartis received clearance by the FDA to start this phase I study.
- 09 May 2016 New trial record
- 29 Apr 2016 According to an Ablynx media release, the company has received clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for this phase I study which is expected to initiate in the second quarter of 2016.